What Is Pelthos Therapeutics Inc. (PTHS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pelthos Therapeutics Inc.'s intrinsic value is estimated at $14.40, suggesting the stock is overvalued at its current price of $26.44. With 9 out of 10 models flagging downside (-45.5% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +13.6% (fair value: $30.02), while Bayesian DCF is the most conservative at -77.2% ($6.03). The spread between these extremes — +90.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PTHS?
10 of 13 models are currently active for PTHS. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates PTHS's intrinsic value at $6.03, implying -77.2% downside from the current price. See which stocks rank higher →
How Does PTHS Rank in Biological Products, (No Diagnostic Substances)?
Among 139 Biological Products, (No Diagnostic Substances) stocks, PTHS ranks #59 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Pelthos Therapeutics Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is PTHS a Value Trap?
CirclFi's Value Trap algorithm assigns PTHS a score of 5/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Pelthos Therapeutics Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Pelthos Therapeutics Inc.'s fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +90.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PTHS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PTHS's 10 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad